ArticleFrontiers in medicine2026
Percutaneous endovascular biopsy for the diagnosis of intravascular masses: a single-center retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Intravascular masses remain difficult to characterize with imaging alone, and histopathological confirmation is often required to guide individualized treatment. This study aimed to evaluate the technical success, diagnostic yield, and procedural safety of percutaneous endovascular biopsy (PEB) for the pathological diagnosis of intravascular masses. Methods: We retrospectively reviewed 30 patients (18 men and 12 women; mean age, 55 ± 10 years) who underwent PEB for pathological diagnosis between January 2016 and December 2023 at a single center. Tissue samples were obtained using 7-F biopsy forceps under digital subtraction angiography (DSA) guidance. Technical success, diagnostic yield, and procedure-related complications were analyzed. Results: Technical success was achieved in all patients (100%; 95% CI 88.6%-100%), with a median of three samples (range 3-4) obtained per lesion. No procedure-related complications were observed in this cohort. Histopathological analysis provided a definitive diagnosis in all cases (100%; 95% CI 88.6%-100%). Malignant lesions were identified in 11 patients (36.7%; 95% CI 21.9-54.5%), with hepatocellular carcinoma with vascular invasion being the most common malignant diagnosis. Benign lesions accounted for 19 cases (63.3%; 95% CI 45.5-78.1%) and consisted mainly of fibrous tissue and thrombi. Conclusions: PEB achieved high technical success and diagnostic yield, with no observed procedure-related complications in this selected single-center cohort. These findings suggest that PEB may be a useful diagnostic tool when imaging findings are inconclusive. Larger prospective multicenter studies are required to establish its diagnostic accuracy and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.